Frankfurt - Delayed Quote EUR
Chemomab Therapeutics Ltd. (2QV0.F)
1.0900
+0.0300
+(2.83%)
At close: April 25 at 3:29:01 PM GMT+2
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, CEO & Executive Director | 613.77k | -- | 1982 |
| Ms. Sigal Fattal CPA, M.B.A. | Chief Financial Officer | 438.4k | -- | 1971 |
| Dr. Matthew B. Frankel M.B.A., M.D. | Chief Medical Officer & VP of Drug Development | 681.28k | -- | 1969 |
| Barbara Lindheim | Consulting Vice President of Investor & Public Relations, Strategic Communications | -- | -- | -- |
| Dr. David M. Weiner M.D. | Interim Chief Medical Officer | -- | -- | 1965 |
| Mr. Jack Lawler | Chief Development Officer | -- | -- | -- |
Chemomab Therapeutics Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Corporate Governance
Chemomab Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 7, 2025 at 11:00 AM UTC - May 12, 2025 at 11:00 AM UTC
Chemomab Therapeutics Ltd. Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
PBN.F Alterity Therapeutics Limited
0.0045
+12.50%
6XY.F HBM Holdings Limited
0.9000
+5.88%
FAB.L Fusion Antibodies plc
6.80
-9.09%
TRMED.OL Thor Medical ASA
2.4000
-2.24%
ELIC.ST Elicera Therapeutics AB (publ)
4.3500
+13.73%
FARN.L Faron Pharmaceuticals Oy
202.00
-0.25%
BIOVIC-B.ST Biovica International AB (publ)
0.6980
+9.06%
MEDCL.PA MedinCell S.A.
14.97
+0.13%
VVY.AS Vivoryon Therapeutics N.V.
1.7760
-1.88%
MDCLF MedinCell S.A.
6.98
0.00%